Literature DB >> 25711199

Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis.

Julien Le Nobin1, Andrew B Rosenkrantz2, Arnauld Villers3, Clément Orczyk4, Fang-Ming Deng5, Jonathan Melamed5, Artem Mikheev2, Henry Rusinek2, Samir S Taneja4.   

Abstract

PURPOSE: We compared prostate tumor boundaries on magnetic resonance imaging and radical prostatectomy histological assessment using detailed software assisted co-registration to define an optimal treatment margin for achieving complete tumor destruction during image guided focal ablation.
MATERIALS AND METHODS: Included in study were 33 patients who underwent 3 Tesla magnetic resonance imaging before radical prostatectomy. A radiologist traced lesion borders on magnetic resonance imaging and assigned a suspicion score of 2 to 5. Three-dimensional reconstructions were created from high resolution digitalized slides of radical prostatectomy specimens and co-registered to imaging using advanced software. Tumors were compared between histology and imaging by the Hausdorff distance and stratified by the magnetic resonance imaging suspicion score, Gleason score and lesion diameter. Cylindrical volume estimates of treatment effects were used to define the optimal treatment margin.
RESULTS: Three-dimensional software based registration with magnetic resonance imaging was done in 46 histologically confirmed cancers. Imaging underestimated tumor size with a maximal discrepancy between imaging and histological boundaries for a given tumor of an average ± SD of 1.99 ± 3.1 mm, representing 18.5% of the diameter on imaging. Boundary underestimation was larger for lesions with an imaging suspicion score 4 or greater (mean 3.49 ± 2.1 mm, p <0.001) and a Gleason score of 7 or greater (mean 2.48 ± 2.8 mm, p = 0.035). A simulated cylindrical treatment volume based on the imaging boundary missed an average 14.8% of tumor volume compared to that based on the histological boundary. A simulated treatment volume based on a 9 mm treatment margin achieved complete histological tumor destruction in 100% of patients.
CONCLUSIONS: Magnetic resonance imaging underestimates histologically determined tumor boundaries, especially for lesions with a high imaging suspicion score and a high Gleason score. A 9 mm treatment margin around a lesion visible on magnetic resonance imaging would consistently ensure treatment of the entire histological tumor volume during focal ablative therapy.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  computer-assisted; image processing; magnetic resonance imaging; pathology; prostatic neoplasms; risk

Mesh:

Year:  2015        PMID: 25711199      PMCID: PMC4726648          DOI: 10.1016/j.juro.2015.02.080

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

Review 1.  Prostate cancer: multiparametric MR imaging for detection, localization, and staging.

Authors:  Caroline M A Hoeks; Jelle O Barentsz; Thomas Hambrock; Derya Yakar; Diederik M Somford; Stijn W T P J Heijmink; Tom W J Scheenen; Pieter C Vos; Henkjan Huisman; Inge M van Oort; J Alfred Witjes; Arend Heerschap; Jurgen J Fütterer
Journal:  Radiology       Date:  2011-10       Impact factor: 11.105

2.  Object matching algorithms using robust Hausdorff distance measures.

Authors:  D G Sim; O K Kwon; R H Park
Journal:  IEEE Trans Image Process       Date:  1999       Impact factor: 10.856

3.  Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology.

Authors:  Mekhail Anwar; Antonio C Westphalen; Adam J Jung; Susan M Noworolski; Jeffry P Simko; John Kurhanewicz; Mack Roach; Peter R Carroll; Fergus V Coakley
Journal:  Radiother Oncol       Date:  2014-01-17       Impact factor: 6.280

4.  Patterns of spread of adenocarcinoma in the prostate as related to cancer volume.

Authors:  J E McNeal; O Haillot
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

Review 5.  How good is MRI at detecting and characterising cancer within the prostate?

Authors:  Alexander P S Kirkham; Mark Emberton; Clare Allen
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

6.  MR imaging-guided focal cryoablation in patients with recurrent prostate cancer.

Authors:  Joyce G R Bomers; Derya Yakar; Christiaan G Overduin; J P Michiel Sedelaar; Henk Vergunst; Jelle O Barentsz; Frank de Lange; Jurgen J Fütterer
Journal:  Radiology       Date:  2013-03-22       Impact factor: 11.105

7.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

Authors:  Deanna L Langer; Theodorus H van der Kwast; Andrew J Evans; Laibao Sun; Martin J Yaffe; John Trachtenberg; Masoom A Haider
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

8.  Focal laser ablation of prostate cancer: definition, needs, and future.

Authors:  Pierre Colin; Serge Mordon; Pierre Nevoux; Mohammed Feras Marqa; Adil Ouzzane; Philippe Puech; Gregory Bozzini; Bertrand Leroux; Arnauld Villers; Nacim Betrouni
Journal:  Adv Urol       Date:  2012-05-16

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

10.  A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.

Authors:  C Parker; D Muston; J Melia; S Moss; D Dearnaley
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

View more
  40 in total

1.  Intra- and interreader reproducibility of PI-RADSv2: A multireader study.

Authors:  Clayton P Smith; Stephanie A Harmon; Tristan Barrett; Leonardo K Bittencourt; Yan Mee Law; Haytham Shebel; Julie Y An; Marcin Czarniecki; Sherif Mehralivand; Mehmet Coskun; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Baris Turkbey
Journal:  J Magn Reson Imaging       Date:  2018-12-21       Impact factor: 4.813

2.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10

3.  Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology.

Authors:  Alan Priester; Shyam Natarajan; Pooria Khoshnoodi; Daniel J Margolis; Steven S Raman; Robert E Reiter; Jiaoti Huang; Warren Grundfest; Leonard S Marks
Journal:  J Urol       Date:  2016-07-30       Impact factor: 7.450

Review 4.  Ablative options for prostate cancer management.

Authors:  Rafael R Tourinho-Barbosa; Lucas Teixeira Batista; Xavier Cathelineau; Javier Sanchez-Macias; Rafael Sanchez-Salas
Journal:  Turk J Urol       Date:  2020-10-09

5.  3D Registration of mpMRI for Assessment of Prostate Cancer Focal Therapy.

Authors:  Clément Orczyk; Andrew B Rosenkrantz; Artem Mikheev; Arnauld Villers; Myriam Bernaudin; Samir S Taneja; Samuel Valable; Henry Rusinek
Journal:  Acad Radiol       Date:  2017-11-06       Impact factor: 3.173

6.  Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.

Authors:  Marc A Bjurlin; Peter R Carroll; Scott Eggener; Pat F Fulgham; Daniel J Margolis; Peter A Pinto; Andrew B Rosenkrantz; Jonathan N Rubenstein; Daniel B Rukstalis; Samir S Taneja; Baris Turkbey
Journal:  J Urol       Date:  2019-10-23       Impact factor: 7.450

Review 7.  Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Authors:  M J Connor; M A Gorin; H U Ahmed; R Nigam
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-12       Impact factor: 5.554

Review 8.  The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.

Authors:  Ariel A Schulman; Christina Sze; Efrat Tsivian; Rajan T Gupta; Judd W Moul; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

Review 9.  Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer.

Authors:  Baris Turkbey; Anna M Brown; Sandeep Sankineni; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  CA Cancer J Clin       Date:  2015-11-23       Impact factor: 508.702

Review 10.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.